- Home
- / NattoPharma
NattoPharma
Revenue
KR214.5 M
FY, 2020
NattoPharma Summary
Company Summary
- Overview
- NattoPharma engages in the research and development of vitamin K2 for applications in the marketplace for functional food and dietary supplements. The Company's flagship brand is MenaQ7, a vitamin K2 as menaquinone-7 for bone and cardiovascular health. It also provides marketing and sales support services.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2004
- HQ
- Oslo, NO | view all locations
- Website
- http://www.nattopharma.com/
- Cybersecurity rating
Table of Contents
Key People
Frode Marc Bohan, Chairman of the Board
Kjetil Ramsøy, Chief Executive Officer
Rudi de Man, Vice President Sales & Business Development
LocationsView all
2 locations detected
Oslo HQ
Norway
2B Lilleakerveien
Egkomi, Nicosia
Cyprus
1st floor, office 101, Prodromou 75
NattoPharma Financials
Summary Financials
- Revenue (FY, 2020)
- kr214.5M
- Gross profit (FY, 2020)
- kr94.8M
- Net income (FY, 2020)
- kr68.6M
- Cash (FY, 2020)
- kr42.5M
- EBIT (FY, 2020)
- kr43.3M